Fertility and Sterility
Volume 91, Issue 3 , Pages 884-892, March 2009

Recanalization and particle exclusion after embolization of uterine arteries in sheep: a long-term study

  • Alexandre Laurent, M.D., Ph.D.

      Affiliations

    • Department of Interventional Neuroradiology, AP-HP, Lariboisière Hospital, Paris, France
    • Center for Research of Interventional Imaging (CR2i), AP-HP, INRA, Paris, France
    • Corresponding Author InformationReprint requests: Alexandre Laurent, M.D., Ph.D., APHP - Hopital Lariboisiere, Department of Interventional Neuroradiology, 3 rue A. Pare, F-75010 Paris, France (FAX: 33-1-49-95-83-56).
  • ,
  • Michel Wassef, M.D.

      Affiliations

    • Department of Pathology, AP-HP, Lariboisière Hospital, Paris, France
  • ,
  • Julien Namur, Ph.D.

      Affiliations

    • Department of Pathology, AP-HP, Lariboisière Hospital, Paris, France
  • ,
  • Jacques Martal, Vet. D. Ph.D.

      Affiliations

    • Unit of Physiology of Reproduction, INRA, Paris, France
  • ,
  • Denis Labarre, Ph.D.

      Affiliations

    • Biomaterials and Polymers, CNRS UMR 8612, Paris, France
  • ,
  • Jean-Pierre Pelage, M.D., Ph.D.

      Affiliations

    • Department of Radiology and Interventional Imaging, AP-HP, Ambroise Paré Hospital, Paris, France

Received 20 August 2007; received in revised form 5 December 2007; accepted 5 December 2007. published online 05 March 2008.

Objective

To compare the long-term evolution of uterine arteries after embolization with the two most commonly used embolic agents for fibroid embolization: nonspherical polyvinyl alcohol (PVA) particles and trisacryl gelatin microspheres (TGMS).

Design

Prospective study.

Setting

University-based interventional radiology, pathology, and reproductive physiology units.

Animal(s)

Two groups of 10 sheep embolized in the uterine artery.

Intervention(s)

Embolization of the uterine artery with either 600–1000 μm nonspherical polyvinyl alcohol (PVA) particles or with 700–900 μm trisacryl gelatin microspheres (TGMS). Animals were synchronized and naturally inseminated. Animals were killed at 26 months.

Main Outcome Measure(s)

Uteri were examined pathologically for vessel size, site of occlusion, recanalization rate of vessels, and particle location within the vascular wall.

Result(s)

The PVA particles were more numerous in the vessels' lumen than the TGMS particles (13.3 ± 20.8 vs. 2.5 ± 2.7), were located more proximally than TGMS (97% vs. 68% in the trunk and first branches of the uterine artery), and were found almost exclusively in the intima (99.2%). In contrast, 54.4% of the TGMS particles were found in the intima, and 45.6% partially or totally excluded. The rate of recanalization was not statistically significantly different for PVA and TGMS (65.2% vs. 60.6%).

Conclusion(s)

The long-term evolution of uterine arteries was different after uterine artery embolization with PVA and TGMS because PVA particles formed large-sized aggregates that occluded proximal vessels and remained in the vessel intima. Microspheres occluded more distal vessels, and about 50% of them were partially or totally excluded from the vessel.

Key Words: Embolization, uterine artery, fertility, animal model, foreign body reaction, vessel remodeling

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 A.L. and M.W. contributed equally to the work, and therefore should both be considered first authors.

 A.L. and M.W. are the inventors of TGMS, the patent of which assignee is Assistance Publique Hôpitaux de Paris (APHP). J.N. has nothing to disclose. J.M. has nothing to disclose. D.L. has nothing to disclose. J.-P.P. has nothing to disclose.

 Presented at the Cardiovascular and Interventional Society of Europe (CIRSE), Antalya, Turkey, September 20–24, 2003.

PII: S0015-0282(07)04197-0

doi:10.1016/j.fertnstert.2007.12.015

Fertility and Sterility
Volume 91, Issue 3 , Pages 884-892, March 2009